CDK4 and breast carcinoma: With the development of CDK4/6 inhibitors, PI3Kinase inhibitors, checkpoint inhibitors, and antibody-drug conjugates, there are many developing treatment options available to metastatic breast cancer patients, thus rendering application of these results unclear in the current breast cancer treatment landscape.